Holen Sie sich die Stockscreener-App
47.69
1.32%
0.62
Handel nachbörslich:
47.36
-0.33
-0.69%
Schlusskurs vom Vortag:
$47.07
Offen:
$46.98
24-Stunden-Volumen:
343.85K
Relative Volume:
0.87
Marktkapitalisierung:
$3.06B
Einnahmen:
$88.55M
Nettoeinkommen (Verlust:
$-157.85M
KGV:
-17.28
EPS:
-2.76
Netto-Cashflow:
$-137.92M
1W Leistung:
-1.65%
1M Leistung:
+10.75%
6M Leistung:
+27.51%
1J Leistung:
+234.20%
1-Tages-Spanne:
$46.34
$48.88
1-Wochen-Bereich:
$42.62
$48.88
52-Wochen-Spanne:
$13.85
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2024 Earnings Call Transcript - Insider Monkey
Kymera Therapeutics to Participate in Upcoming November Investor Conferences - The Manila Times
Mirae Asset Global Investments Co. Ltd. Boosts Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
UBS Group Has Lowered Expectations for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - MarketBeat
Immunology to take front seat at Kymera - The Pharma Letter
Earnings call: Kymera Therapeutics advances in immunology and oncology By Investing.com - Investing.com Australia
Earnings call: Kymera Therapeutics advances in immunology and oncology - Investing.com India
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Simply Wall St
Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report - Yahoo Finance
FY2024 Earnings Estimate for KYMR Issued By Leerink Partnrs - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
(KYMR) Long Term Investment Analysis - Stock Traders Daily
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates - MSN
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus - MSN
Kymera Therapeutics (NASDAQ:KYMR) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
The Latest Analyst Ratings For Kymera Therapeutics - Benzinga
Kymera Therapeutics (NASDAQ:KYMR) Receives "Buy" Rating from Truist Financial - MarketBeat
Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK
B.Riley boosts Kymera stock target amid cautious optimism for STAT6 degrader - Investing.com Australia
Kymera Therapeutics stock target lifted by Stifel, buy rating on oncology pivot - Investing.com UK
Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Kymera Therapeutics Reports Q3 2024 Earnings and Strategic Shift - TipRanks
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap DownTime to Sell? - MarketBeat
Kymera Therapeutics (KYMR) Q3 2024 Earnings: EPS Misses at -$0.8 - GuruFocus.com
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update - StockTitan
Kymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To K - GuruFocus.com
Preview: Kymera Therapeutics's Earnings - Benzinga
Insights Ahead: Kymera Therapeutics's Quarterly Earnings - Benzinga
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - MSN
Kymera Therapeutics (KYMR) Scheduled to Post Earnings on Thursday - MarketBeat
Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases - StockTitan
Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31 - ForexTV.com
Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium - The Manila Times
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decrease in Short Interest - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Trading 6.8% HigherStill a Buy? - MarketBeat
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decline in Short Interest - MarketBeat
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
SG Americas Securities LLC Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera Therapeutics (NASDAQ:KYMR) & Novozymes A/S (OTCMKTS:NVZMY) Critical Comparison - Defense World
How To Trade (KYMR) - Stock Traders Daily
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance - Yahoo Finance
Kymera advances novel STAT6 degrader into clinical trials - Investing.com
Kymera Therapeutics' Application for KT-621 Gets FDA Clearance - Marketscreener.com
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader - The Manila Times
Kymera advances novel STAT6 degrader into clinical trials By Investing.com - Investing.com UK
The Manufacturers Life Insurance Company Raises Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Takes Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Dimensional Fund Advisors LP Buys 53,176 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors - Seeking Alpha
Algert Global LLC Purchases 4,622 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by ProShare Advisors LLC - Defense World
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):